Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Aura Biosciences Inc(AURA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for AURA
09/24/2026: AURA (2-star) is currently NOT-A-BUY. Pass it for now.
Aura Biosciences is a clinical-stage biotechnology company focused on developing targeted, vision-sparing therapies for ocular and other solid tumor cancers using its proprietary VDC platform. The company's main strength lies in its innovative drug delivery technology and its focus on underserved oncology markets. Its primary growth story centers on the potential for Bel-sar to become a new standard of care for choroidal melanoma. However, the firm faces significant execution and binary risks, as it currently lacks commercial revenue and depends entirely on successful clinical outcomes and regulatory approvals. Aura is best suited for growth-oriented investors who can tolerate high volatility and long-term development risks.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Aura offers high growth potential contingent on clinical success but carries significant binary risk. |
| Momentum investor | Mixed fit | Momentum depends heavily on clinical data announcements which can cause sharp, volatile price movements. |
| Value investor | Weak fit | The company lacks current earnings or revenue, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | Aura is a clinical-stage biotech and does not pay dividends. |
| Low-risk investor | Weak fit | High volatility and the risks associated with drug development are unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks often experience sharp fluctuations based on trial results and funding news. |
| Valuation risk | Medium / high | Valuations are highly speculative as they are based on future potential rather than current financial performance. |
| Competition risk (oncology) | Medium | Established players have more resources to develop competing therapies. |
| Business quality | Medium | While the platform is innovative, the lack of commercialized products limits current franchise strength. |
| Dividend income | Low / none | The company is in an investment phase and does not generate income for shareholders. |
| Execution risk | High | The company must successfully navigate complex clinical and regulatory pathways to reach commercialization. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -58.54% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/24/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 624.30M USD | Price to earnings Ratio - | 1Y Target Price 16.6 |
Price to earnings Ratio - | 1Y Target Price 16.6 | ||
Volume (30-day avg) 936.2K shares | Beta 0.4 | 52 Weeks Range 4.73 - 9.54 | Updated Date 09/24/2026 |
52 Weeks Range 4.73 - 9.54 | Updated Date 09/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.73 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Researching and testing Bel-sar and other VDC candidates. | The company currently spends money to develop drugs and does not have product sales. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 316.02M | Price to Sales(TTM) - |
Enterprise Value 316.02M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -5.68 | Shares Outstanding 103.70M | Shares Floating 79.63M |
Shares Outstanding 103.70M | Shares Floating 79.63M | ||
Percent Insiders 2.7 | Percent Institutions 94.29 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Aura Biosciences Inc
Exchange NASDAQ | Headquarters Boston, MA, United States | ||
IPO Launch date 2021-10-29 | President, CEO & Director Ms. Natalie C. Holles | ||
Sector Healthcare | Industry Biotechnology | Full time employees 113 | Website https://www.aurabiosciences.com |
Full time employees 113 | Website https://www.aurabiosciences.com | ||
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.